Sunesis sinks on Phase III Qinprezo survival miss
This article was originally published in Scrip
Executive Summary
Sunesis Pharmaceuticals sank 78% to $1.46 per share on 6 October when the company said Qinprezo (vosaroxin) did not meet the Phase III VALOR clinical trial's primary endpoint of a statistically significant improvement in median overall survival compared with placebo.
You may also be interested in...
Stockwatch: The TIGER That Came To Lilly
The reasons behind Lilly's latest clinical failure had much less to do with the indication and more to do with repeating the past mistakes of Inspire and Sunesis. Unfortunately, that same die has already been cast for the trials of Biogen and Ophthotech that are due to report imminently.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.